177 related articles for article (PubMed ID: 33341407)
1. Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment.
Harruff EE; Kil J; Ortiz MGT; Dorgan D; Jain R; Poth EA; Fifer RC; Kim YJM; Shoup AG; Flume PA
J Cyst Fibros; 2021 Mar; 20(2):288-294. PubMed ID: 33341407
[TBL] [Abstract][Full Text] [Related]
2. Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin.
Garinis A; Gleser M; Johns A; Larsen E; Vachhani J
J Cyst Fibros; 2021 Mar; 20(2):278-283. PubMed ID: 32713806
[TBL] [Abstract][Full Text] [Related]
3. High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis.
Al-Malky G; Dawson SJ; Sirimanna T; Bagkeris E; Suri R
J Cyst Fibros; 2015 Mar; 14(2):248-54. PubMed ID: 25127922
[TBL] [Abstract][Full Text] [Related]
4. The implementation of an aminoglycoside induced ototoxicity algorithm for people with cystic fibrosis.
Elson EC; Meier E; Oermann CM
J Cyst Fibros; 2021 Mar; 20(2):284-287. PubMed ID: 32811788
[TBL] [Abstract][Full Text] [Related]
5. Chirp-Evoked Otoacoustic Emissions and Middle Ear Absorbance for Monitoring Ototoxicity in Cystic Fibrosis Patients.
Garinis AC; Keefe DH; Hunter LL; Fitzpatrick DF; Putterman DB; McMillan GP; Gold JA; Feeney MP
Ear Hear; 2018; 39(1):69-84. PubMed ID: 28708814
[TBL] [Abstract][Full Text] [Related]
6. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.
Mulheran M; Hyman-Taylor P; Tan KH; Lewis S; Stableforth D; Knox A; Smyth A
Antimicrob Agents Chemother; 2006 Jul; 50(7):2293-9. PubMed ID: 16801404
[TBL] [Abstract][Full Text] [Related]
7. Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions.
Al-Malky G; Suri R; Dawson SJ; Sirimanna T; Kemp D
Int J Audiol; 2011 Feb; 50(2):112-22. PubMed ID: 21265638
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
9. Exploration of the relationship between cumulative exposure to tobramycin and ototoxicity in patients with cystic fibrosis.
Madaule J; Valenzuela F; Mittaine M; Gallois Y; Baladi B; Murris M; Calmels MN; Concordet D; Gandia P
J Cyst Fibros; 2023 Sep; 22(5):944-948. PubMed ID: 37088635
[TBL] [Abstract][Full Text] [Related]
10. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis.
Prescott WA; Nagel JL
Pharmacotherapy; 2010 Jan; 30(1):95-108. PubMed ID: 20030477
[TBL] [Abstract][Full Text] [Related]
11. Effects of chronic tobramycin treatment on distortion product otoacoustic emissions.
Katbamna B; Homnick DN; Marks JH
Ear Hear; 1999 Oct; 20(5):393-402. PubMed ID: 10526861
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis.
Dong M; Rodriguez AV; Blankenship CA; McPhail G; Vinks AA; Hunter LL
J Antimicrob Chemother; 2021 Oct; 76(11):2923-2931. PubMed ID: 34379758
[TBL] [Abstract][Full Text] [Related]
13. Extended-interval aminoglycoside administration for children: a meta-analysis.
Contopoulos-Ioannidis DG; Giotis ND; Baliatsa DV; Ioannidis JP
Pediatrics; 2004 Jul; 114(1):e111-8. PubMed ID: 15231982
[TBL] [Abstract][Full Text] [Related]
14. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
Prescott WA
Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
[TBL] [Abstract][Full Text] [Related]
15. High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients.
Geyer LB; Menna Barreto SS; Weigert LL; Teixeira AR
Braz J Otorhinolaryngol; 2015; 81(6):589-97. PubMed ID: 26480907
[TBL] [Abstract][Full Text] [Related]
16. Hearing thresholds at high frequency in patients with cystic fibrosis: a systematic review.
Caumo DTM; Geyer LB; Teixeira AR; Barreto SSM
Braz J Otorhinolaryngol; 2017; 83(4):464-474. PubMed ID: 27894912
[TBL] [Abstract][Full Text] [Related]
17. Ebselen attenuates tobramycin-induced ototoxicity in mice.
Gu R; Longenecker RJ; Homan J; Kil J
J Cyst Fibros; 2021 Mar; 20(2):271-277. PubMed ID: 32147183
[TBL] [Abstract][Full Text] [Related]
18. The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis.
Garinis AC; Cross CP; Srikanth P; Carroll K; Feeney MP; Keefe DH; Hunter LL; Putterman DB; Cohen DM; Gold JA; Steyger PS
J Cyst Fibros; 2017 May; 16(3):401-409. PubMed ID: 28238634
[TBL] [Abstract][Full Text] [Related]
19. High dosage tobramycin treatment of children with cystic fibrosis. Bacteriological effect and clinical ototoxicity.
Thomsen J; Friis B
Int J Pediatr Otorhinolaryngol; 1979 Jul; 1(1):33-40. PubMed ID: 553884
[TBL] [Abstract][Full Text] [Related]
20. Intravenously delivered aminoglycoside antibiotics, tobramycin and amikacin, are not ototoxic in mice.
Ogier JM; Lockhart PJ; Burt RA
Hear Res; 2020 Feb; 386():107870. PubMed ID: 31864009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
